The FDA recently announced that it approved a record-breaking number of generic drugs in October 2018.
The FDA recently announced that it approved a record-breaking number of generic drugs in October 2018.
In total, the FDA put out 128 approval actions last month. Of these, 110 generic drugs were approved, and 18 other generic drugs were tentatively approved. This number includes 23 first generics for products that previously lacked competition, and 17 complex generics (FDA’s data also include 1 biosimilar adalimumab product).
“The FDA plays an important role in approving high-quality medicines and promoting more generic drug competition. Over the past 2 consecutive years, the agency approved record numbers of generic drugs,” said FDA Commissioner Scott Gottlieb, MD. “Now we’re beginning the new fiscal year by breaking another record, this time with the highest number of approved or tentatively approved generics ever in a month.”
Gottlieb explained that, through the agency’s efforts, generic drugs that entered the market from January 2017 through July 2018 were able to save consumers $26 billion. Additionally, these efforts are also reducing the number of review cycles for generic drug applications, making the process more efficient so the agency is able to dedicate its resources to getting the “quality generic medications” to patients sooner.
Furthermore, last month, the FDA also issued a series of guidance documents aimed at advancing the development of generic transdermal and topical delivery systems. These guidance documents allow for increased transparency from the FDA to applicants seeking approval of generic versions of complex products by explaining how to more efficiently prepare better and more complete applications.
“We’ll continue our efforts to increase competition and help lower costs for patients with our Drug Competition Action Plan and will do so by continuing to advance policies that increase the efficiency of our generic drug program and working to approve high quality generic medicines that meet our standards,” said Gottlieb.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.